If you have been reading about Cardarine and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Linus Pauling Online a Pauling portal created by Oregon State University Libraries Crick, Francis, "The Impact of Linus Pauling on Molecular Biology" (transcribed from video at the 1995 Oregon State University symposium) The Ava Helen and Linus Pauling Papers at the Oregon State University Libraries The Pauling Catalogue Center for Oral History. "Linus C. Pauling". Science History Institute. Sturchio, Jeffrey L. (1987-04-06). Linus C. Pauling, Transcript of an Interview Conducted by Jeffrey L. Sturchio in Denver, Colorado on 6 April 1987 (PDF). Philadelphia, PA: Chemical Heritage Foundation. The Pauling Blog Linus Pauling (1901–1994) Berkeley Conversations With History interview Linus Pauling Centenary Exhibit Linus Pauling from The Dictionary of Unitarian and Universalist Biography Archived October 16, 2018, at the Wayback Machine "It's in the Blood! A Documentary History of Linus Pauling, Hemoglobin and Sickle Cell Anemia – Special Collections & Archives Research Center – Oregon State University". Oregon State University Library. Retrieved 2015-02-25. The Linus Pauling Institute at Oregon State University Publications of Pauling The Linus Pauling Papers – Profiles in Science, National Library of Medicine Linus Pauling Archived July 19, 2019, at the Wayback Machine Documentary produced by Oregon Public Broadcasting Oral history interview with Linus C. Pauling from Science History Institute Digital Collections
On March 10, 2014, the first Dunkin' Donuts/Baskin-Robbins combination store in Southern California opened in Ramona. This is Dunkin' Donuts' third California shop to open, following shops in Barstow and on Camp Pendleton. Since March 2014, Dunkin' Donuts has opened several additional locations throughout California, including the Los Angeles area. Dunkin' Donuts shops opened in the San Francisco Bay Area in Walnut Creek, Half Moon Bay, and American Canyon in 2016, as well as South San Francisco and Fremont, in 2017.
Inca cuisine originated in pre-Columbian times within the Inca civilization from the 13th to the 16th century. The Inca civilization stretched across many regions on the western coast of South America (specifically Peru), and so there was a great diversity of unique plants and animals used for food. The most important plant staples involved various tubers, roots, and grains; and the most common sources of meat were guinea pigs, llamas, fish, and other aquatic and terrestrial organisms (305-307). Cuisine was heavily influenced by the Inca's food storage system, social gatherings and celebrations, and social status (308-315).
Sources: en.wikipedia.org
==== United States ==== As of 2018, Zipline was working with the FAA to develop rules for drone operation beyond the line of sight. During the COVID-19 pandemic in 2020, the FAA granted a Part 107 waiver to Novant Health in partnership with Zipline for the delivery of medical supplies and personal protective equipment to facilities in North Carolina. The company plans to offer deliveries to homes. On November 18, 2021, Zipline started a trial service with Walmart for e-commerce shopping deliveries in Pea Ridge, Arkansas. The service, selectable to online shoppers using a special mobile app, could deliver to all residences within 50 miles (80 km) of a particular Walmart store in Pea Ridge during daylight hours. On June 21, 2022, the license "Package Delivery by Drone (Part 135)" was granted. On October 4, 2022, Zipline began commercial delivery services in Salt Lake City, Utah, in partnership with Intermountain Healthcare. On September 18, 2023, the FAA announced it had authorized Zipline to begin making commercial deliveries beyond the line of sight without visual observers. In April 2025, Zipline began making deliveries for Walmart in the Dallas–Fort Worth metroplex using Platform 2 drones.
Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency. Lonapegsomatropin is a prodrug of somatropin. Lonapegsomatropin was approved for medical use in the United States in August 2021, and in the European Union in January 2022.
EiPLA, also known as N-ethyl-N-isopropyllysergamide or as lysergic acid ethylisopropylamide, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is an isomer of ETH-LAD.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.